Glycogenosis type 11 (GSD 11) is one of the more than ten glycogen storage diseases recognized at present as separate genetic entities.28 Characteristic for this disease is the organelle bound, lysosomal, accumulation of glycogen as opposed to the cytoplasmic accumulation of glycogen in the other glycogenoses. The disease was described first in 1932 by the Dutch pathologist, J.C. Pompe, from whom it lends its name Pompe's disease. 34 The name "acid maltase deficiency" was introduced in 1963 after identification of the missing enzyme.14 That publication by H.G. Hers on the primary defect in Pompe's disease has accelerated the subsequent discovery of lysosomal enzyme deficiencies in more than 30 other lysosomal storage diseases. In addition, deficiencies of nonenzymic lysosomal proteins were discovered.
Since the discovery of the primary lysosomal a-glucosidase deficiency in GSD I1 important new information has been acquired on the structure and function of the enzyme, and progress has been made with elucidating the underlying genetic defect in case of a-glucosidase deficiency. Enzyme therapy is under development. This minireview starts with a brief description of the clinical phenotypes of GSD I1 and a review of recent findings pertaining to the structure and function of lysosomal a-glucosidase. T h e genotype-phenotype correlation is addressed with reference to the mutations discovered so far and the residual a-glucosidase activity in cultured fibroblasts from a large series of patients. Original data on the prenatal diagnosis by chorionic villus sampling in 42 pregnancies at risk are presented, and the prospects for enzyme therapy are discussed.
THE CLINICAL PHENOTYPE
Among patients with GSD I1 a pronounced variation is observed with regard to age of onset and clinical presentation. This has led to the distinction of three subtypes of the disease, an infantile, juvenile, and adult In patients with the infantile form of GSD I1 symptoms become apparent within the first 3 months of life. Mostly, poor motor development and failure to thrive are noticed first. On clinical examination there is generalized hypotonia with muscle wasting, increased respiration rate with sternal retractions, moderate enlargement of the liver, and protrusion of the tongue. Ultrasound examination of the heart shows a progressive hypertrophic cardiomyopathy , eventually leading to insufficient cardiac output. The ECG is characterized by marked left axis deviation, a short PR interval, large QRS complexes, inverted T waves, and ST depressions. The disease shows a rapidly progressive course leading to cardiorespiratory failure within the first year of life. On histological examination at autopsy lysosomal glycogen storage is observed in various tissues, most pronounced in heart and skeletal muscle.
Patients with the adult form of GSD I1 may not experience symptoms within the first two decades of life. In this clinical subtype only skeletal muscles are involved with predilection of those of the limb girdle, the trunk and the diaphragm. Difficulty in climbing stairs is often the initial complaint. The respiratory impairment varies considerably. It can dominate the clinical picture, or it is not experienced by the patient until late in life.7 The eldest patient recorded at the University Hospital Rotterdam was referred at the age of 53, and died at the age of 72 because of respiratory insufficiency, which is the main cause of death in late onset GSD 11.
Besides infantile and adult variants an intermediate juvenile subtype is distinguished. In these patients symptoms usually become apparent in the first decade of life. As in adult GSD 11, skeletal muscle weakness is the major problem, cardiac involvement does not occur. In many cases nightly ventilatory support is ultimately needed. Pulmonary infections in combination with wasting of the respiratory muscles are life threatening and mostly become fatal before the third decade. On autopsy in late onset (juvenile and adult) cases glycogen storage is solely encountered in skeletal muscles. However, in some rare cases storage of glycogen has been described in vascular smooth muscle cells, leading to an aneurysm of the basilar or other intracranial a r t e r i e~.~~'~'
In practice, the clinical appearance of Pompe's disease is a spectrum with an early onset and rapidly progressive phenotype with cardiac involvement at one end and a late onset slowly progressive 
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LYSOSOMAL a-GLUCOSIDASE (ACID MALTASE)
Lysosomal or acid a-glucosidase is the best name for this enzyme since the substrate specificity is not limited to maltose, and the catalytic activity not to hydrolysis of the 1,4-glycosidic bond. The natural substrate is glycogen. When engulfed by the lysosoma1 system,6 glycogen is degraded to glucose whereby both the a-1,4 and a-1,6 linkages are cleaved. Also, activity for a-1,2 and a-1,3 diglycosidic bonds has been reported,26 which implies that carbohydrate structures other than glycogen may serve as natural substrate. The enzyme consists of 952 amino acids as deduced from the cDNA sequence and shows structural similarity with the intestinal enzymes sucrase and i~omaltase.'~ It is assumed that the three enzymes have arisen from a common ancestral gene. 15, 20 The newly synthesized lysosomal a-glucosidase precursor has a signal peptide at the N-terminal end for guiding the nascent protein to the lumen of the endoplasmic r e t i c~l u m '~ where N-linked glycosylation occurs at all the seven avail- Posttranslational processing during transport through the Golgi complex and trans-Golgi network, and in the lysosomes, leads to a stepwise mass reduction from 110 kd via 95 kd to 76 kd and finally 70 kd.9,31,36350 T h e posttranslational modification is complex and involves the proteolytic removal of both N-and C-terminal peptides in fixed order, and further, a partial alteration of the initial carbohydrate structures. T h e conformational changes are essential for the development of catalytic activity. 18950 Figure 2 shows schematically the location of the seven glycosylation sites (Gl-G7) and the places of proteolytic cleavage. Also summarized in this figure are the amino acid substitutions that have been found in GSD I1 patients (discussed separately).
NATURE OF THE LYSOSOMAL a-GLUCOSIDASE DEFICIENCY IN GSD II
Activity. The discovery of acid maltase deficiency in a severe case of infantile Pompe's disease has been the first important step in elucidating the molecular basis of GSD II.14 The "same" enzyme deficiency was later also discovered in late onset variants of the disease. 53 The cause of this clinical heterogeneity remained obscure. The hypothesis of a coexistent deficiency of acid and neutral maltase activities in the severe form of GSD I1 as compared to a single acid a-glucosidase deficiency in the milder clinical forms was raised but could not be ~u b s t a n t i a t e d .~~ An alternative presumption that patients with a milder form of the disease would have a higher residual a-glucosidase activity was made, 17, 29, 35, 38, 41, 43 but left unexplained the mild clinical phenotype of some adult atients with T o reevaluate the latter presumption we have recently compared the level of residual a-glucosidase activity in cultured fibroblasts from patients with different clinical phenotypes. These cells are for several reasons more suitable for this type of study than muscle biopsy specimens or leukocytes: (i) fibroblast cell lines can be established and collected over the years and can be stored frozen in liquid nitrogen without loss of viability and enzyme activity, ensuring a large sample size; (ii) the culture conditions are well controlled and the condition of the cells can be monitored by visual inspection and by recording the growth rate; (iii) the lysosomal glycogen accumulation in cultured fibroblasts is moderate compared to muscle fibers35 and does not induce cellular damage with concurrent effects on lysosomal enzyme a c t i~i t i e s ,~'~~ moreover, the pathological changes in muscle tissue vary 10cally;~ and (iv) leukocyte preparations, which are the preferred material for the routine assay of many lysosomal enzymes, are not ideal for a-glucosidase assay, probably because of high and variable levels of neutral maltase activities. T h e influence of neutral maltase activities in fibroblasts is negligible, provided that the assay is performed at low pH.
The data obtained with fibroblasts were collected in our diagnostic department over a 15-year period, and are summarized in Figure 3 . T h e activity of each fibroblast cell line is depicted separately. The control series includes 84 cell lines from healthy individuals and ranges from 42 to 160 nmol/h per milligram protein with an average activity of 97.5. Twenty of the 24 cell lines from patients with adult GSD I1 have activities ranging an exceptionally low residual activity. L 3 8 D 518 16 from 7 to 22 nmol/h per milligram (i.e., 7-23% of the average control activity), and four cell lines have significantly lower activities. Four cell lines were available from patients with juvenile GSD 11, all with a low but significant activity (2-6%). Patients with severe infantile GSD I1 form the most homogeneous population in that none of the cell Iines exhibits more than 1% residual activity. Thus, Figure 3 shows a logical correlation between the level of residual activity and the course of the disease. A similar correlation has been observed in a small series of muscle cell cultures. 43 This correlation can be taken as a starting point for understanding the cause of clinical diversity. Effort can then be devoted to finding an explanation for the relatively mild clinical phenotype of some adult patients with an exceptionally low a-glucosidase activity. We have done so in one particular case of adult GSD I1 with 4% residual activity and noticed that a-glucosidase was normally synthesized, but disappeared during the subsequent formation of mature enzyme. Immunocytochemistry at the ultrastructural level suggested that the deficiency of lysosomal a-glucosidase activity was compensated in part by expansion and activation of the lysosomal system: a phenomenon seen in the affected but not in the unaffected muscle fibers.49 Table 1 , and the resulting amino acid substitutions are indicated by position in Figure 1 . References to the publications in which these mutations were reported are given in the footnote of Table 1 . Also included are mutations discovered in our laboratory that remained as yet unpublished. The genetic heterogeneity in GSD I1 is immediately evident. The mutations are spread over most of the exons and are of different nature. Single base-pair deletions, (double) insertions, and larger deletions occur besides missense and nonsense mutations. Also, splice defects with loss of coding sequences have been reported. Frequent mutations are the exon 18 deletion, which occurs in the Dutch patient population with an allele frequency of 0.13 among infants and adults, and the exon 2 deletion in adults (allele frequency 0.35). Also AT525 and Pro545Leu seem to be more common mutations (see Table 1 for references).
Some mutations are predictably deleterious by creating a stop codon at the (very) 5' end of the coding sequence (e.g., AT525 and Arg40Stop) or by leading to substantial loss of coding sequence (e.g., the deletions of exon 18, exon 2, and nt 1456-1468). Other mutations are obviously harmless because they do not result in an amino acid substitution or are also found in healthy individuals (polymorphism). Caution has to be taken with predicting the effect of most other mutations. Evolutionary conservative amino acid substitutions such as Asp645Glu can be deleterious. Very drastic alterations such as Glu-Lys remain without effect when occurring at position 689, but are deleterious at position 52 G271A  C324T  G596A  C642T  A668G  A921T  A1 203G  C1374T  A1 581 G  G1726A  C1727G  G1917A  G2065A  A21 33G  G2238C  A2338G  G2446A  A2553G  C2780T  C2808T  G2862A  AG2998lAG2999  C3002T  C3082T  G3086C significance of a mutation, it is necessary to perform a detailed analysis by site-directed mutagenesis of the "wild-type'' cDNA followed by expression in eukaryotic cells. T o correlate genotype and phenotype it is essential to know the effect of a given mutation exactly. The frequent occurrence of compound heterozygotes is a complicating factor because the two mutant allele products have a combined effect. T o investigate the genotype-phenotype correlation in GSD I1 we have expressed the mutant allele products transiently in COS cells. The residual activity in the COS cell expression system appeared to correlate percentagewise with the residual activity in the patients' fibroblasts. lo,' Moreover, similar defects in synthesis and posttranslational modification were observed in COS cells as in fibroblasts. Thus, mutation analysis via the COS cell system demonstrates the causal relation between mutation, defective enzyme biosynthesis, and loss of enzymatic function. However, this sophisticated assay is not per se more informative about the cause of clinical diversity than the level of a-glucosidase activity realized (in fibroblasts) by the two mutant allele products in natural coexistence. Mutation analysis has the advantage that it provides the means to diagnose with certainty carriers in families at risk, which may be problematic by enzyme assay. Furthermore, insight in the genotypephenotype correlation and better understanding of enzyme structure and function, obtained by mutation analysis, will help to design a strategy for therapy.
PRENATAL DIAGNOSIS OF GSD II
Prenatal diagnosis for the infantile type of GSD I1 is reliably possible by chorionic villus sampling (CVS) or amniocentesis. We have performed prenatal analysis in 114 pregnancies at risk for GSD I1 and diagnosed 23 affected fetuses. The first 5 cases in this series, concerning the assay of a-glucosidase in cultured amniotic fluid cells, were reported nearly 20 years ago. 30 The diagnostic test is complicated by the generally low activity of a-glucosidase in first-passage amniotic fluid cells (10-65 nmol/h per milligram protein) compared to 42-160 nmol/h per milligram in cultured skin fibroblasts. Activities as low as 3-4 nmoYh per milligram have been measured in a few pregnancies with an unaffected heterozygous fetus. However, with optimal accuracy and sufficient experience, these low carrier levels can be distinguished reliably from the virtually complete deficiency of a-glucosidase in amniocytes from affected fetuses (i.e., < 1 nmoVh per milligram).
T h e introduction of CVS has strongly improved the prenatal diagnosis of GSD 11. The most important advantage of CVS obviously is that it is done at a much earlier gestational age (10-12 weeks) than amniocentesis (15-16 weeks). Moreover, the enzyme analysis can be carried out directly on the chorionic biopsy making the diagnosis available within a day. The use of chorionic villi (CV) has also facilitated the diagnosis of GSD 11, because the activity of a-glucosidase in normal CV is much higher than in amniotic fluid cells, which results in a better separation of values indicating a carrier or an affected fetus, respectively.
A definitive and correct diagnosis could be made by direct analysis of the CV in 41 of the 42 pregnancies (Table 2 ). In 10 cases an almost complete deficiency of a-glucosidase left no doubt about the diagnosis of an affected fetus. In che remaining cases the activity was normal (n = 20), moderately reduced as expected for heterozygotes (n = 111, or strongly reduced in 1 case (n = 1). In this exceptional case amniocentesis also indicated heterozygosity .
Previous reports on small series of first-trimester diagnoses for GSD I1 have emphasized the risk of maternal tissue contamination of CV samples? or have anticipated the possible presence of neutral a-glucosidase activity in CV and have used an immunoprecipitation method' or maltose as substrate to prevent such interfering acti~ity.~' We have used a simple and rapid assay with artificial 4-methylumbelliferyl a-D-glucopyranoside substrate at pH 4.0. The absence of activity in the CV of 10 affected pregnancies indicates that neither interfering enzyme activity nor the presence of maternal tissue or enzyme has played a role in these cases.
THERAPY
The most exciting progress in the development of therapy for lysosomal storage diseases is the effectiveness of enzyme therapy in type 1 Gaucher's disease.1933352 The rationale of the approach is that (macro)molecular compounds are able to enter cells by endocytosis and reach the lysosomal sysCell surface receptors can function as efficient mediators in this process. 42 The first attempt at enzyme therapy for lysosomal diseases dates from 1965 when a patient suffering from infantile GSD IT received intravenous injections of a-glucosidase from Aspergllus niger.2 A 5-month-old infant was treated for 116 days with a similar enzyme p r e p a r a t i~n . '~ An increase of enzyme activity in the liver was recorded and a clearance of lysosomal glycogen was noted. However, the positive effects could not be maintained. T h e treatment was stopped after 4 months because of a developing immune nephritis. The patient died of cardiorespiratory insufficiency. At postmortem examination the liver and spleen pathology was typical for advanced GSD 11. Also, other attempts at therapy with a-glucosidase from human placenta were unsuccessful. Without present-day knowledge, these early trials were bound to fail, because of insufficient quality and quantity of the administered enzyme. Moreover, in these trials it was not attempted to facilitate a-glucosidase uptake via cell surface receptors. The protocol for treatment of Gaucher's disease with enzyme therapy prescribes the use of placental glucocerebrosidase with modified carbohydrate side chains so that the enzyme binds to mannose receptors on the cell surface of affected macrophages in liver (Kupffer cells), spleen, and bone marrow.4o Enzyme therapy is at present applied almost as a routine for the treatment of type 1 Gaucher's disease and appears to be effective although questions remain about the exact mechanism of action.
Following the same basic principles we started to develop models for (re)testing the potential effect of a-glucosidase administration to patients with GSD 11. The most essential information obtained so far is that enzyme administered to cultured fibroblasts and muscle cells is taken up in an efficient manner when containing mannose 6-phosphate groups, enabling the enzyme to bind to the mannose 6-phosphate r e~e p t o r .~~*~~,~~~~~,~~ Evidence for lysosomal targeting and function was obtained most notably by the resulting breakdown of stored glycogen. The relatively long half-life of the ingested enzyme (approximately 6-9 days) is favorable for successful application. In a more realistic model system, preparations of human placental and bovine testis a-glucosidase were administered intravenously to healthy mice in a dose of 180 pg per animal. The enzyme was recovered in various organs up to 9 days after injection. Most of it appeared to be taken u p by liver and spleen, virtually independent of the mannose 6-phosphate content. The enzyme was not found in brain indicating that the blood-brain barrier is not passed. Most importantly, however, uptake was obtained also in heart and skeletal muscle, the target organs in GSD 11. The increase of a-glucosidase activity obtained with bovine testis a-glucosidase containing mannose 6-phosphate residues was higher than with placental enzyme lacking this recognition signal. 46 In theory, the 40% increase obtained should be sufficient to supplement the enzyme deficiency of patients, under the assumption that cellular pathology does not ensue at activity levels above 30% of the average control level (according to the data in Fig. 2) .
Although these results are promising, the ultimate effect of enzyme therapy in GSD I1 can only be tested in clinical trails in humans, preferably preceded by tests in animal models. With respect to the latter, the development of a mouse model of GSD I1 via mutagenesis of the murine a-glucosidase gene in embryonic stem cells is in progress. Animal models of lysosomal storage diseases have already proven their value. For instance, mice with a natural P-glucuronidase deficiency (mucopolysaccharidosis type VIIISly syndrome in humans) have been used for investigating the effect of bone marrow transplantation, enzyme infusion, and implantation of a neo-organ with glucuronidase-producing fibroblast^.^^,^^,^^ A prerequisite to enzyme therapy in lysosomal storage diseases including GSD I1 is the realization of large scale production of (recombinant) enzyme. Production in genetically modified CHO cells is an option already applied for the production of glucocerebrosidase. An alternative approach we are exploring is production of human recombinant a-glucosidase in the milk of transgenic mammals. There are still obstacles toward therapy for GSD 11, but the goal is challenging.
